Avalyn Pharma Inc.
Clinical trials sponsored by Avalyn Pharma Inc., explained in plain language.
-
New inhaled therapy aims to slow lung scarring in progressive fibrosis
Disease control Recruiting nowThis study tests an inhaled version of the drug pirfenidone (AP01) in 375 adults with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Participants receive either a high dose, low dose, or placebo twice daily for 52 weeks, alongside their u…
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated May 26, 2026 05:24 UTC
-
New inhaled therapy could ease lung scarring without pills
Disease control Recruiting nowThis study tests an inhaled version of the drug nintedanib (AP02) in 160 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants inhale the drug or a placebo twice daily for 12 weeks. The goal is to see if AP02 improv…
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated May 26, 2026 05:16 UTC
-
Lung scarring drug safety tracked in Long-Term extension trial
Disease control Recruiting nowThis study looks at the long-term safety of an inhaled medication for people with progressive lung scarring (pulmonary fibrosis). It is for those who already completed an earlier Avalyn Pharma study. The goal is to monitor side effects and lung function over time, not to cure the…
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated May 26, 2026 05:06 UTC